Actualités SeaStar Medical Holding Corporation - ICU | Actions NASDAQ

SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market

DENVER, Feb. 03, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical...

SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market

DENVER, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical...

SeaStar Medical Adds Fifth Hospital Customer for QUELIMMUNE

DENVER, Jan. 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

DENVER, Jan. 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...

FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

Study to be conducted under $3.6 million NIH grant DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar...

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

DENVER, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...

SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial

DENVER, Dec. 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...

SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications

U.S. total addressable market for five initial indications is $25 to $33 billion REMINDER: Business Update...

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

DENVER, Dec. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...

SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult AKI Pivotal Trial

DENVER, Dec. 03, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...

SeaStar Medical to Present at Noble Capital Markets’ NobleCon20 on December 4, 2024

DENVER, Nov. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical’s Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares

SeaStar Medical urges stockholders to vote FOR all proxy proposals prior to the Special Meeting of Stockholders...

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

DENVER, Nov. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...

SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

DENVER, Nov. 13, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar...

FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

This represents the fourth indication granted a Breakthrough Device Designation for the SCD by FDA DENVER...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

SeaStar Medical Holding Corporation (ICU)

Outils de qualité professionnelle, pour des investisseurs individuels.

ICU Actualités

SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market

SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market

SeaStar Medical Adds Fifth Hospital Customer for QUELIMMUNE

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial

SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult AKI Pivotal Trial

SeaStar Medical to Present at Noble Capital Markets’ NobleCon20 on December 4, 2024

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical’s Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

SeaStar Medical Holding Corporation (ICU) Actualités

SeaStar Medical Holding Corporation (ICU)

Outils de qualité professionnelle, pour des investisseurs individuels.

ICU Actualités

SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market

SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market

SeaStar Medical Adds Fifth Hospital Customer for QUELIMMUNE

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial

SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult AKI Pivotal Trial

SeaStar Medical to Present at Noble Capital Markets’ NobleCon20 on December 4, 2024

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical’s Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités